LYFT Inc vs Vaxcyte Inc. Common Stock — how do they compare? LYFT Inc trades at $16.36 (market cap $6.20B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| LYFT | PCVX | |
|---|---|---|
Market Cap | $6.20B | $10.51B |
Volume | 12,306,511 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $24.57 | $73.82 |
52-Week Low | $12.65 | $40.32 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.48, up 2.3% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 2.38 and net income margin of 42.32%. Recent developments include European expansion and a $272.5M legal settlement. Cash flow improved significantly to $891M in 2025 from negative levels in prior years, while revenue grew to $6.32B.
Outlook remains positive with analyst consensus target of $18.07, though mixed earnings performance and regulatory risks persist. The stock offers value with low valuation multiples but faces competition and execution challenges in international markets. Recent technical indicators show overbought conditions near resistance at $17.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →